Abstracts tagged "ustekinumab and treatment response"

Abstract Number: 861 • 2019 ACR/ARP Annual Meeting
Cutaneous Lupus Erythematosus Disease Area & Severity Index (CLASI) Demonstrates Thresholds for Detection of Treatment Response in a Phase-2, Placebo-Controlled Trial of Ustekinumab in SLE
Victoria Werth¹, Bevra Hahn ², George Tsokos ³, Shawn Rose ⁴, Kaiyin Fei ⁴, Yun Gregan ⁴, Robert Gordon ⁴, Kim Hung Lo ⁴ and Ronald van Vollenhoven ⁵, ¹Hospital of the Univ of PA and Veteran’s Administration Med Center, Philadelphia, PA, ²University of California, Los Angeles, CA, ³Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands
Background/Purpose: Ustekinumab (UST), an anti-IL-12/23 p40 monoclonal antibody, showed significantly greater improvement at week (wk) 24 compared with placebo (PBO) in Systemic Lupus Erythematosus Disease…